Navigation Links
Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
Date:6/3/2010

TOKYO, June 3 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today the completion of the initial tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc. (Nasdaq: OSIP).

The initial offer period expired at 12:00 midnight, New York City time, on June 2, 2010. Computershare Trust Company, N.A., the depositary for the tender offer, has advised that a total of 48,415,727 shares were validly tendered and not withdrawn prior to the expiration of the initial offer period, representing approximately 79% of OSI's issued and outstanding shares. All shares validly tendered and not withdrawn have been accepted for payment. 5,014,478 additional shares were tendered subject to guaranteed delivery procedures prior to the expiration of the initial offer period.  The total number of shares validly tendered, plus the shares tendered subject to guaranteed delivery procedures, represents approximately 87% of OSI's issued and outstanding shares.  

Astellas also announced today that it would make available a subsequent offer period commencing immediately and expiring at 12:00 midnight, New York City time on June 7, 2010, unless extended.  During the subsequent offer period, any shares validly tendered will be immediately accepted for payment, and tendering stockholders will promptly thereafter be paid $57.50 per share in cash, less any withholding taxes and without interest, which is the same amount per share that was offered and paid to OSI stockholders who previously tendered into the initial offer.

The procedures for tendering shares during the subsequent offer period are the same as during
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
2. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
5. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
6. GSK Announces Revised Product Labels for Serevent® and Advair®
7. US Oncology Announces iKnowMed(TM) Technology Platform
8. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
9. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
10. Elbit Imaging Ltd. Announces First Quarter Results for 2010
11. CardioGenics Announces Update Regarding Status of Merck Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... therapy to treat obesity, metabolic diseases and other gastrointestinal ... has been appointed to the Board of Directors, effective ... Class II Director until the 2018 annual meeting or ... Ms. McDougal has served in an executive capacity in ...
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
Breaking Medicine Technology:EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
... Calif., Jan. 4, 2011 Intarcia Therapeutics, Inc. today ... will present at the 29th Annual JP Morgan Healthcare ... 2011 at the Westin St. Francis Hotel in San ... About Intarcia Intarcia Therapeutics, ...
... Pa., Jan. 4, 2011 Owner and medical director of ... her practice and is now offering Pixel Perfect™ ... CO2 laser from Alma Lasers. "I,m very ... Cirillo-Hyland said. "As a long time provider of aesthetic laser ...
Cached Medicine Technology:Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference 2Philadelphia's Victoria A. Cirillo-Hyland, M.D. Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... , Infectious diseases researchers from the University of Pittsburgh School of Medicine are ... of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine ... reduce health care costs. , Annually, more than 8.6 million adverse drug ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... Hispanic Health notes that while an overwhelming number of Hispanics believe people ... , The overwhelming 70 percent of participants queried said making diet changes was ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... solutions for drugs, biologics and consumer health products, today welcomed the announcement by ... OPKO’s New Drug Application for a new treatment for chronic kidney disease (CKD) ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... must weigh risks, benefits, experts say , , TUESDAY, Nov. ... data confirms that some common inhalers don,t boost the ... as chronic obstructive pulmonary disease (COPD). , In fact, ... in patients with COPD, the fourth biggest killer in ...
... 25 Nationwide Health Properties, Inc. (NYSE: NHP ) ... U.K. nursing home property company that may be in default ... the similarity of the names, it wanted to clarify that ... , Nationwide Health Properties, Inc. is a real ...
... (FRG) is pleased to announce the hiring of Dr. ... Operations. Katyal will be joining them from,West Penn Hospital, ... and Past President of the Pittsburgh Radiology Society. , ... widely regarded as the preeminent cardiovascular imager in,Western Pennsylvania. ...
... public event held today in New Orleans, the Department ... jointly announced the selection of adjacent downtown sites for ... projects, called the Veterans Affairs Medical Center and the ... greatly needed health care capability lost in New Orleans ...
... Nov. 25 The U.S. military provides its members ... commitments. But a researcher at Kansas State University ... be enough to maintain a supreme equilibrium. , ... of psychology at K-State, and colleagues have been studying ...
... components to determine levels of halogens , ... Minneapolis ... a leading materials testing laboratory, is helping companies adhere ... led to concerns regarding the environmental and health impact of halogens ...
Cached Medicine News:Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3Health News:Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff 2Health News:VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects 2Health News:VA and Louisiana State University Announce Site Selections for New Orleans Medical Center Projects 3Health News:K-State Psychologist Studies Ways to Improve Soldiers' Work-Life Relationship 2Health News:Innovatech Labs, Assisting Companies in Adhering to Halogen-Free Manufacturing Standards Aimed at Protecting the Environment 2
Galilean Loupes...
... Over 40 cm field-of-view enables high-quality ... system with scalable 32-channel architecture. New powerful ... 3.0T imaging up to 80 mT/m ... SAR management to fully exploit the power ...
... fusion system represents a breakthrough for patients ... spine. The system gathers bone during decompression, ... of bone into the implant's chamber produces ... harvest from the iliac crest. The BAK/C ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: